These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 23126686)

  • 1. Intensification of diabetes medication and risk for 30-day readmission.
    Wei NJ; Wexler DJ; Nathan DM; Grant RW
    Diabet Med; 2013 Feb; 30(2):e56-62. PubMed ID: 23126686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of insulin therapy in patients with type 2 diabetes mellitus: beyond basal insulin.
    Blak BT; Smith HT; Hards M; Curtis BH; Ivanyi T
    Diabet Med; 2012 Jul; 29(7):e13-20. PubMed ID: 22268988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hospital readmission and emergency department use based on prescribing patterns in patients with severely uncontrolled type 2 diabetes mellitus.
    Lee PH; Franks AS; Barlow PB; Farland MZ
    Diabetes Technol Ther; 2014 Mar; 16(3):150-5. PubMed ID: 24224752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month 'proof-of-concept' study.
    Owens DR; Luzio SD; Sert-Langeron C; Riddle MC
    Diabetes Obes Metab; 2011 Nov; 13(11):1020-7. PubMed ID: 21679291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initiating insulin therapy in elderly patients with Type 2 diabetes: efficacy and safety of lispro mix 25 vs. basal insulin combined with oral glucose-lowering agents.
    Wolffenbuttel BH; Klaff LJ; Bhushan R; Fahrbach JL; Jiang H; Martin S
    Diabet Med; 2009 Nov; 26(11):1147-55. PubMed ID: 19929994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction in glycated albumin can predict change in HbA1c: comparison of oral hypoglycaemic agent and insulin treatments.
    Won HK; Kim KJ; Lee BW; Kang ES; Cha BS; Lee HC
    Diabet Med; 2012 Jan; 29(1):74-9. PubMed ID: 21781151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Self-titration of biphasic insulin aspart 30/70 improves glycaemic control and allows easy intensification in a Dutch clinical practice.
    Ligthelm RJ
    Prim Care Diabetes; 2009 May; 3(2):97-102. PubMed ID: 19285933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial.
    Bretzel RG; Nuber U; Landgraf W; Owens DR; Bradley C; Linn T
    Lancet; 2008 Mar; 371(9618):1073-84. PubMed ID: 18374840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: A longitudinal study of a US administrative claims database.
    Tong L; Pan C; Wang H; Bertolini M; Lew E; Meneghini LF
    Diabetes Obes Metab; 2018 Apr; 20(4):831-839. PubMed ID: 29119712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensor-augmented pump therapy lowers HbA(1c) in suboptimally controlled Type 1 diabetes; a randomized controlled trial.
    Hermanides J; Nørgaard K; Bruttomesso D; Mathieu C; Frid A; Dayan CM; Diem P; Fermon C; Wentholt IM; Hoekstra JB; DeVries JH
    Diabet Med; 2011 Oct; 28(10):1158-67. PubMed ID: 21294770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment intensification in patients with type 2 diabetes who failed metformin monotherapy.
    Fu AZ; Qiu Y; Davies MJ; Radican L; Engel SS
    Diabetes Obes Metab; 2011 Aug; 13(8):765-9. PubMed ID: 21457427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised, controlled trial of self-monitoring of blood glucose in patients with type 2 diabetes receiving conventional insulin treatment.
    Nauck MA; Haastert B; Trautner C; Müller UA; Nauck MA; Heinemann L;
    Diabetologia; 2014 May; 57(5):868-77. PubMed ID: 24445534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study.
    Blonde L; Merilainen M; Karwe V; Raskin P;
    Diabetes Obes Metab; 2009 Jun; 11(6):623-31. PubMed ID: 19515182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes.
    Thomsen RW; Baggesen LM; Søgaard M; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
    Diabetologia; 2015 Oct; 58(10):2247-53. PubMed ID: 26277380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fasting plasma glucose 6-12 weeks after starting insulin glargine predicts likelihood of treatment success: a pooled analysis.
    Karl D; Zhou R; Vlajnic A; Riddle M
    Diabet Med; 2012 Jul; 29(7):933-6. PubMed ID: 22413808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
    Esposito K; Ciotola M; Maiorino MI; Gualdiero R; Schisano B; Ceriello A; Beneduce F; Feola G; Giugliano D
    Ann Intern Med; 2008 Oct; 149(8):531-9. PubMed ID: 18936501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting.
    Yoon NM; Cavaghan MK; Brunelle RL; Roach P
    Clin Ther; 2009 Jul; 31(7):1511-23. PubMed ID: 19695400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of injection-meal interval usage and its association with variables of metabolic control in patients with Type 1 and Type 2 diabetes.
    Müller N; Kloos C; Frank T; Ristow M; Wolf G; Müller UA
    Diabet Med; 2011 Feb; 28(2):223-6. PubMed ID: 21219434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.